Pharmaceuticals Search Engine [selected websites]

Wednesday, September 17, 2008

Magnisense : MIAplex, a unique magnetic technology to detect multiple biological agents simultaneously

Paris, May 20, 2008Magnisense, a diagnostics company that develops and markets magnetic immunoassays, announces MIAplex™, a new magnetic bead technology that allows simultaneous multiparametric testing of biological samples, delivering improved speed and cost-performance ratios.

MIAplex™ builds on Magnisense’s MIAtek™, a robust and versatile detection technology making possible the development of magnetic immunoassays using magnetic beads as labels for monoparametric testing. It differs from Magnisense’s existing offer and competing technology by allowing the simultaneous use of several magnetic beads with varying magnetic properties for labeling several parameters in one sample – without the need for spatial resolution of key parameters. No other company worldwide offers such ability.

MIAplex™ has wide-ranging application potential, including medical and veterinary diagnostics, food inspection, environmental and security monitoring. The MIAplex™ approach is especially suited to biosensing of samples with practically unlimited volume. It can be used for example for testing drugs of abuse in drivers or occupational medicine, for infectious agents in blood, or for bacteria in foodstuffs...

...

About Magnisense

Magnisense develops and markets magnetic immunoassays. These next-generation bioassays improve rapid diagnostic performance for human and animal diagnostics, food safety and environmental protection testing. They are based on magnetic bead markers, which can be used to achieve the accuracy of laboratory testing with the ease of use of rapid test methods.

Exploiting a unique feature of magnetic bead markers, Magnisense’s MIAtek™ technology provides true quantification of a large volume sample. The magnetic signal is free of interference from environmental factors, permitting a more sensitive and reproducible detection than possible with other surface-restricted approaches common in lateral flow rapid testing.

Magnisense is developing two test formats for different application areas:
MIAstrip™: Point of care testing with a single dose, producing objective, quantifiable and traceable results via a portable reader. MIAstrip enables the identification of a target via detection of known markers for a number of diseases including avian flu, cardiac disease, tetanus, and bacterial, viral, parasitic or mycotic infections.
MIAflo™: Disposable cartridges for detection of targets, such as bacterial contamination in food products, e.g. Listeria and Salmonella, or in water, e.g. Legionella, with a sensitivity that brings a significant reduction in testing time... Magnisense's Press Release - Communiqué de Presse Magnisense -